At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the interim analysis of the randomised, double-blind, placebo-controlled, phase 3 HELIOS trial, which evaluated ibrutinib, a Bruton’s tyrosine kinase inhibitor, combined with bendamustine and rituximab (BR) versus vs BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma.
HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL
26th August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?